Importantly, although CLK2 expression level was independent of MYC amplification in samples from the published clinical breast cancer data (Curtis et al, 2012; Pereira et al, 2016; Appendix Fig S6A), patients with both amplified MYC and high CLK2 expression show poor prognosis, with the lowest medium survival time relative to patients with only amplified MYC or those with only highly expressed CLK2 (Appendix Fig S6B). The gene discussed is CLK2; the disease is breast carcinoma.